Tumor-associated enzymes can diminish or even negate the immune system’s ability to fight off cancerous cells by making subtle but damaging structural changes to anti-cancer antibodies.
Listen in as Dr. Zhiqiang An, of the University of Texas Health Science Center, discusses how his lab developed a set of novel antibodies to visualize these changes that has now led to a new therapeutic strategy to combat tumor evasion.
Abcam will process your personal data in strict accordance with its privacy policy which can be found here. This will include sending you updates about Abcam, our products, and resources we think would be of interest to you. You can unsubscribe and manage your marketing preferences by clicking the link at the bottom of every email we send. By filling out this form you consent to Abcam sharing your details with your local, authorized distributor for the purpose of answering your query.
Dr. Zhiqiang An is Professor of Molecular Medicine, the Robert A. Welch Distinguished University Chair in Chemistry, and Director of the Texas Therapeutics Institute at the University of Texas Health Science Center at Houston.
